cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29423036
title: Supplementary Material for: Pharmaceutical Treatment of People with Dementia during the SARS-Cov-2 Pandemic in Germany: polypharmacy, anticholinergic medication, and antidementia medication

description: Introduction. Dementia patients are at increased risk of polypharmacy and inappropriate medication, exacerbating cognitive decline. The SARS-Cov-2 pandemic constrained access to medical care and monitoring services for dementia patients, potentially worsening medication-related issues. We analyzed the medical treatment of dementia patients during the SARS-Cov-2 pandemic in Bavaria, particularly regarding polypharmacy, anticholinergic medication, and antidementia medication.
Methods. The Bavarian Ambulatory COVID-19 Monitor (BaCoM) is a longitudinal registry study conducted in Bavaria, Germany. Participants in need of nursing care with baseline data during the SARS-Cov-2 pandemic were included in our detailed analysis (N=345, dementia sample n=96 with a dementia diagnosis and/or antidementia medication treatment). Descriptive statistics and group comparisons (dementia vs. non-dementia sample; within the dementia sample: participants with vs. without antidementia medication; participants with vs. without anticholinergic medication in both the non-dementia sample and the dementia sample) are provided.
Results. In the dementia sample, 91.7% of the patients received ≥4 medication (polypharmacy), 21.9% even ≥10 medication. Prescription of ≥1 anticholinergic medication was found in 65.6%, and prescription of ≥1 antidementia medication in 31.2% of the dementia sample. People with antidementia medication received a higher number of medication (p=.025) and had higher levels of education (p=.016). People with anticholinergic medication also received a higher number of medication (both in the dementia sample and in the whole sample p&lt;.001). 
Conclusions. Despite known risks and adverse effects, polypharmacy as well as the use of anticholinergic and antidementia medication were common among individuals with dementia. Compared to pre-pandemic studies, levels of polypharmacy and anticholinergic medication but not of antidementia medication appeared slightly elevated in people with dementia. Because of the associated risks, polypharmacy and potentially inappropriate medication require regular review (and when possible reduction) in people with dementia. In crisis situations like a pandemic, an outreach approach might be necessary for this patient group.
DOI: 10.6084/m9.figshare.29423036.v1
title: Supplementary Material for: Pharmaceutical Treatment of People with Dementia during the SARS-Cov-2 Pandemic in Germany: polypharmacy, anticholinergic medication, and antidementia medication

description: Introduction. Dementia patients are at increased risk of polypharmacy and inappropriate medication, exacerbating cognitive decline. The SARS-Cov-2 pandemic constrained access to medical care and monitoring services for dementia patients, potentially worsening medication-related issues. We analyzed the medical treatment of dementia patients during the SARS-Cov-2 pandemic in Bavaria, particularly regarding polypharmacy, anticholinergic medication, and antidementia medication.
Methods. The Bavarian Ambulatory COVID-19 Monitor (BaCoM) is a longitudinal registry study conducted in Bavaria, Germany. Participants in need of nursing care with baseline data during the SARS-Cov-2 pandemic were included in our detailed analysis (N=345, dementia sample n=96 with a dementia diagnosis and/or antidementia medication treatment). Descriptive statistics and group comparisons (dementia vs. non-dementia sample; within the dementia sample: participants with vs. without antidementia medication; participants with vs. without anticholinergic medication in both the non-dementia sample and the dementia sample) are provided.
Results. In the dementia sample, 91.7% of the patients received ≥4 medication (polypharmacy), 21.9% even ≥10 medication. Prescription of ≥1 anticholinergic medication was found in 65.6%, and prescription of ≥1 antidementia medication in 31.2% of the dementia sample. People with antidementia medication received a higher number of medication (p=.025) and had higher levels of education (p=.016). People with anticholinergic medication also received a higher number of medication (both in the dementia sample and in the whole sample p&lt;.001). 
Conclusions. Despite known risks and adverse effects, polypharmacy as well as the use of anticholinergic and antidementia medication were common among individuals with dementia. Compared to pre-pandemic studies, levels of polypharmacy and anticholinergic medication but not of antidementia medication appeared slightly elevated in people with dementia. Because of the associated risks, polypharmacy and potentially inappropriate medication require regular review (and when possible reduction) in people with dementia. In crisis situations like a pandemic, an outreach approach might be necessary for this patient group.
DOI: 10.6084/m9.figshare.29423039
title: Supplementary Material for: Metabolomic Profiling Identifies Early Biomarkers of Frailty, Balance Impairment, and Fall Risks in Older Adults

description: Introduction: The global aging population poses significant challenges to healthcare, with frailty, balance impairment, and fall risks being prominent issues. However, the conventional clinical assessments often fail to detect early signs of these conditions. This study aimed to explore the potential of Metabolomics in early identification of biomarkers related to frailty, poor balance, and fall risks in older adults.
Methods: We analyzed plasma samples from 110 participants aged 25 to 98 years using untargeted metabolomic analysis. Clinical assessments, including Instrumental Activities of Daily Living (IADL), Morse Fall Risk Scale, Timed Up and Go (TUG), Fried Frailty Criteria, etc., were performed. We examined the correlation between metabolomic results, aging-related blood tests, and clinical assessments. Statistical analysis and pathway analysis were used to identify key metabolic alterations.
Results: The metabolomics analysis identified 914 metabolites matching in the human metabolome database, with 293 metabolites significantly correlated with age. Metabolomic profiles showed distinct alterations in older adults, with significant metabolic changes observed in the Old-Old group, particularly in pathways related to Lipid Metabolism, Sphingolipid Signaling, and Fatty Acid Metabolism. A new age classification based on metabolic profiles revealed significant differences in frailty risks across groups, with metabolic signatures linked to poor balance and fall risks. 
Conclusion: Metabolomics offers a promising approach to identify early biomarkers of frailty, balance impairment, and fall risks in older adults. The integration of metabolic profiles with clinical assessments could lead to more precise and personalized healthcare interventions, improving fall prevention strategies and frailty management. Future studies with larger cohorts are needed to validate these findings and explore the clinical utility of Metabolomics in aging-related healthcare.
DOI: 10.6084/m9.figshare.29423039.v1
title: Supplementary Material for: Metabolomic Profiling Identifies Early Biomarkers of Frailty, Balance Impairment, and Fall Risks in Older Adults

description: Introduction: The global aging population poses significant challenges to healthcare, with frailty, balance impairment, and fall risks being prominent issues. However, the conventional clinical assessments often fail to detect early signs of these conditions. This study aimed to explore the potential of Metabolomics in early identification of biomarkers related to frailty, poor balance, and fall risks in older adults.
Methods: We analyzed plasma samples from 110 participants aged 25 to 98 years using untargeted metabolomic analysis. Clinical assessments, including Instrumental Activities of Daily Living (IADL), Morse Fall Risk Scale, Timed Up and Go (TUG), Fried Frailty Criteria, etc., were performed. We examined the correlation between metabolomic results, aging-related blood tests, and clinical assessments. Statistical analysis and pathway analysis were used to identify key metabolic alterations.
Results: The metabolomics analysis identified 914 metabolites matching in the human metabolome database, with 293 metabolites significantly correlated with age. Metabolomic profiles showed distinct alterations in older adults, with significant metabolic changes observed in the Old-Old group, particularly in pathways related to Lipid Metabolism, Sphingolipid Signaling, and Fatty Acid Metabolism. A new age classification based on metabolic profiles revealed significant differences in frailty risks across groups, with metabolic signatures linked to poor balance and fall risks. 
Conclusion: Metabolomics offers a promising approach to identify early biomarkers of frailty, balance impairment, and fall risks in older adults. The integration of metabolic profiles with clinical assessments could lead to more precise and personalized healthcare interventions, improving fall prevention strategies and frailty management. Future studies with larger cohorts are needed to validate these findings and explore the clinical utility of Metabolomics in aging-related healthcare.
DOI: 10.6084/m9.figshare.29423042
title: Supplementary Material for: The path to clinical implementation of DPYD pharmacogenetic testing – long-term experience from an External Quality Assessment (EQA) provider and a university testing center

description: Introduction: Pharmacogenetics (PGx) plays a crucial role in precision medicine by identifying genetic variations that influence drug metabolism. For example, variants in dihydropyrimidine dehydrogenase DPYD have an impact on DPD enzyme activity and consequently on the metabolization of 5-Fluorouracil, which can lead to severe adverse drug reactions. Therefore, pre-emptive DPYD genotyping was endorsed by the European Medicines Agency (EMA) in mid-2020 and subsequently included in national guidelines. In this study, we evaluated the impact of these guidelines on the request behavior for DPYD genotyping at a German university hospital in Mannheim (UMM) and on participation in External Quality Assessment (EQA) schemes in the European setting.
Methods: A retrospective analysis was conducted on 386 DPYD genetic tests performed as part of standard care at the University Medical Center Mannheim from 2015 to 2021. Patient data, including demographics, diagnosis, and treatment, were obtained from electronic health records. Additionally, external quality assessment data from the Reference Institute for Bioanalytics from 2015 to 2023 were analyzed to evaluate the adoption of DPYD testing across European laboratories.
Results: The study observed a significant increase in DPYD genotyping requests at UMM following the EMA recommendation in 2020, with an up to 29-fold increase compared to previous years. Furthermore, a shift from post-treatment to pre-treatment genotyping was observed. DPYD variants were detected in 6.5% of cases, with DPYD HapB3 being the most frequent. EQA data from 23,114 genotypes demonstrated a growing participation in proficiency testing across Europe, indicating broader clinical adoption and confirmed the impact on testing requirements in national guidelines on integration into clinical workflows. 
Conclusion: The integration of DPYD testing into national guidelines has significantly increased its clinical adoption, enhancing patient safety in oncology. However, standardization challenges remain. Further harmonization of guidelines and expansion of PGx testing may further optimize chemotherapy safety in the future.
DOI: 10.6084/m9.figshare.29423042.v1
title: Supplementary Material for: The path to clinical implementation of DPYD pharmacogenetic testing – long-term experience from an External Quality Assessment (EQA) provider and a university testing center

description: Introduction: Pharmacogenetics (PGx) plays a crucial role in precision medicine by identifying genetic variations that influence drug metabolism. For example, variants in dihydropyrimidine dehydrogenase DPYD have an impact on DPD enzyme activity and consequently on the metabolization of 5-Fluorouracil, which can lead to severe adverse drug reactions. Therefore, pre-emptive DPYD genotyping was endorsed by the European Medicines Agency (EMA) in mid-2020 and subsequently included in national guidelines. In this study, we evaluated the impact of these guidelines on the request behavior for DPYD genotyping at a German university hospital in Mannheim (UMM) and on participation in External Quality Assessment (EQA) schemes in the European setting.
Methods: A retrospective analysis was conducted on 386 DPYD genetic tests performed as part of standard care at the University Medical Center Mannheim from 2015 to 2021. Patient data, including demographics, diagnosis, and treatment, were obtained from electronic health records. Additionally, external quality assessment data from the Reference Institute for Bioanalytics from 2015 to 2023 were analyzed to evaluate the adoption of DPYD testing across European laboratories.
Results: The study observed a significant increase in DPYD genotyping requests at UMM following the EMA recommendation in 2020, with an up to 29-fold increase compared to previous years. Furthermore, a shift from post-treatment to pre-treatment genotyping was observed. DPYD variants were detected in 6.5% of cases, with DPYD HapB3 being the most frequent. EQA data from 23,114 genotypes demonstrated a growing participation in proficiency testing across Europe, indicating broader clinical adoption and confirmed the impact on testing requirements in national guidelines on integration into clinical workflows. 
Conclusion: The integration of DPYD testing into national guidelines has significantly increased its clinical adoption, enhancing patient safety in oncology. However, standardization challenges remain. Further harmonization of guidelines and expansion of PGx testing may further optimize chemotherapy safety in the future.
DOI: 10.15468/dl.yg6ssy
title: Occurrence Download

description: A dataset containing 5400 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Europe",
 "TaxonKey is Erica arborea L.",
 "Year 1970-2000"
 ]
}

 The dataset includes 5400 records from 125 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071133-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29423045
title: Supplementary Material for: The relationship between age and cognitive subtypes of Alzheimer’s disease and related dementias

description: Introduction: We aimed to identify cognitive subgroups of clinically diagnosed Alzheimer’s disease (Alzheimer syndrome) and related dementias and test if age of presentation influences patterns of cognitive impairment. 
Methods: Participants were individuals with mild cognitive impairment (n=360), vascular mild cognitive impairment (n=73), Alzheimer syndrome (n=127), vascular dementia (n=32), mixed dementia (n=23), and healthy controls (n=305). Principal Component analysis was run on 25 cognitive variables measured by the Toronto Cognitive Assessment (TorCA). We used hierarchical clustering to identify cognitive subgroups.
Results: We identified seven subgroups. The youngest group was characterized by the lowest scores on the overall TorCA mean, and also on Executive Function, Visuospatial function and Attention, while showing the highest scores on Memory, Orientation, and Language. The oldest clusters had low scores on Memory and Orientation, but higher scores on Attention. The intermediary clusters had similar age and severity distributions. 
Conclusion: The results demonstrate that patterns of cognitive impairment are different in different age groups.
DOI: 10.6084/m9.figshare.29423045.v1
title: Supplementary Material for: The relationship between age and cognitive subtypes of Alzheimer’s disease and related dementias

description: Introduction: We aimed to identify cognitive subgroups of clinically diagnosed Alzheimer’s disease (Alzheimer syndrome) and related dementias and test if age of presentation influences patterns of cognitive impairment. 
Methods: Participants were individuals with mild cognitive impairment (n=360), vascular mild cognitive impairment (n=73), Alzheimer syndrome (n=127), vascular dementia (n=32), mixed dementia (n=23), and healthy controls (n=305). Principal Component analysis was run on 25 cognitive variables measured by the Toronto Cognitive Assessment (TorCA). We used hierarchical clustering to identify cognitive subgroups.
Results: We identified seven subgroups. The youngest group was characterized by the lowest scores on the overall TorCA mean, and also on Executive Function, Visuospatial function and Attention, while showing the highest scores on Memory, Orientation, and Language. The oldest clusters had low scores on Memory and Orientation, but higher scores on Attention. The intermediary clusters had similar age and severity distributions. 
Conclusion: The results demonstrate that patterns of cognitive impairment are different in different age groups.
DOI: 10.6084/m9.figshare.29423051
title: Supplementary Material for: Respiratory Burden in Hematology-Related Bronchiectasis: Clinical Characteristics and Treatable Traits

description: Background: Hematological conditions, mainly allogeneic hematopoietic cell transplantation (allo-HCT) and chronic lymphocytic leukemia (CLL), have known associations with bronchiectasis. However, data on these unique clinical entities remains limited. We aimed to evaluate the clinical characteristics and outcomes of patients with hematology-related bronchiectasis.
Methods: This retrospective study included patients with bronchiectasis following allo-HCT and CLL. Groups were matched and compared to a control group of bronchiectasis from non-hematological conditions (n=126). Clinical variables, radiologic features, and disease outcomes were analyzed.
Results: Overall, 42 patients with bronchiectasis after allo-HCT (median age 59, 36% female) and 63 patients with bronchiectasis and CLL (median age 72, 40% female) were included. Both groups exhibited worse lung functions compared to the control. They had more isolations of Pseudomonas aeruginosa (PA) compared to the control group (21-31% vs. 9%) and less non-tuberculosis mycobacteria (3-5% vs. 21%). Allo-HCT and CLL patients also showed high rates of diffuse bronchiectasis distribution (38% and 40%), hypogammaglobinemia (41% and 71%), and 1-year respiratory hospitalizations (50% and 54%). Only 26% of allo-HCT and 35% of CLL patients saw a pulmonologist, and only 14% performed routine airway clearance. Mortality was higher in both groups compared to controls. The key variables associated with mortality were bronchiolitis obliterans syndrome in the allo-HCT group (HR 11.1, 95% CI 2.9-30.6) and PA isolation in the CLL group (HR 2.96, 95% CI 1.3-6.8). 
Conclusions: Hematology-related BE have distinct clinical and radiologic features with associated morbidity. These findings could help identify at-risk subgroups for early pulmonologist referral.
DOI: 10.6084/m9.figshare.29423051.v1
title: Supplementary Material for: Respiratory Burden in Hematology-Related Bronchiectasis: Clinical Characteristics and Treatable Traits

description: Background: Hematological conditions, mainly allogeneic hematopoietic cell transplantation (allo-HCT) and chronic lymphocytic leukemia (CLL), have known associations with bronchiectasis. However, data on these unique clinical entities remains limited. We aimed to evaluate the clinical characteristics and outcomes of patients with hematology-related bronchiectasis.
Methods: This retrospective study included patients with bronchiectasis following allo-HCT and CLL. Groups were matched and compared to a control group of bronchiectasis from non-hematological conditions (n=126). Clinical variables, radiologic features, and disease outcomes were analyzed.
Results: Overall, 42 patients with bronchiectasis after allo-HCT (median age 59, 36% female) and 63 patients with bronchiectasis and CLL (median age 72, 40% female) were included. Both groups exhibited worse lung functions compared to the control. They had more isolations of Pseudomonas aeruginosa (PA) compared to the control group (21-31% vs. 9%) and less non-tuberculosis mycobacteria (3-5% vs. 21%). Allo-HCT and CLL patients also showed high rates of diffuse bronchiectasis distribution (38% and 40%), hypogammaglobinemia (41% and 71%), and 1-year respiratory hospitalizations (50% and 54%). Only 26% of allo-HCT and 35% of CLL patients saw a pulmonologist, and only 14% performed routine airway clearance. Mortality was higher in both groups compared to controls. The key variables associated with mortality were bronchiolitis obliterans syndrome in the allo-HCT group (HR 11.1, 95% CI 2.9-30.6) and PA isolation in the CLL group (HR 2.96, 95% CI 1.3-6.8). 
Conclusions: Hematology-related BE have distinct clinical and radiologic features with associated morbidity. These findings could help identify at-risk subgroups for early pulmonologist referral.
DOI: 10.60707/8y9a-gq68
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/m3x8-xt94
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/by8m-7s46
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/3v2p-2v72
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/bnek-8q22
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/mkh0-df83
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/ywxe-6y55
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/y2qc-sr75
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/m5kk-y046
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/z0xa-ft70
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/0qm4-2b85
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/bh5j-3b92
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/fd8m-ha43
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/23cw-1a19
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/0865-f259
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/fp6z-mf16
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.5281/zenodo.15751973
title: Gibbs randomness-compression proposition: An efficient deep learning

description: A supplement is provided for the paper: Dataset and the conde for reprduction of the results.    

Gibbs randomness-compression proposition: An efficient deep learning     doi: [10.48550/arXiv.2505.23869](https://arxiv.org/abs/2505.23869)
DOI: 10.5281/zenodo.15751974
title: Gibbs randomness-compression proposition: An efficient deep learning

description: A supplement is provided for the paper: Dataset and the conde for reprduction of the results.    

Gibbs randomness-compression proposition: An efficient deep learning     doi: [10.48550/arXiv.2505.23869](https://arxiv.org/abs/2505.23869)
DOI: 10.60707/hthe-2615
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/zsd5-nn72
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/wca0-v326
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/szye-pf86
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/9ha0-z902
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/9ggv-q257
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/9d5t-j068
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/w9tv-pp97
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/b0dd-j718
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/p322-8d26
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/2g0g-xt91
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/r0ep-nv90
title: N-rich particle on Si chip, aka Neapolitan.
DOI: 10.60707/acy9-k414
title: N-rich particle on Si chip, aka Neapolitan.